Verona Pharma welcomes new directors to the company
Verona Pharma plc, a London-listed drug development company focused on medicines to treat respiratory diseases, has appointed new Non-Executive Directors of the Company
Pharmaceuticals, Biotechnology and Life Sciences
Verona Pharma plc, a London-listed drug development company focused on medicines to treat respiratory diseases, has appointed new Non-Executive Directors of the Company
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .
Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).
AstraZeneca has announced the global completion of the divestment of Caprelsa (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.
The recruitment of patients with ARDS (acute respiratory distress syndrome) for Serendex’s phase II clinical trial – GI HOPE – will begin in November 2015.
The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites and the other half to Youyou Tu for her discoveries concerning a novel therapy against Malaria.
William C. Campbell and Satoshi Ōmura split Nobel prize in Physiology or Medicine 2015 with Youyou Tu, for discoveries regarding novel therapies for some of the most devastating parasitic diseases.
Cell Therapy Ltd will begin the application process for a conditional marketing authorisation (CMA) for Heartcel, the first allogeneic stem cell therapy to regenerate the human heart, in Europe.
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, intends to join the AIM market of the London Stock Exchange by way of a Placing to raise approximately £5 million.
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.